(marketscreener.com) PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable formulation of risperidone microspheres Additional UZEDY data include a new analysis from the Phase 3 RISE trial reinforcing its efficacy and safety profile in adults with schizophrenia ADVANCE, a global...https://www.marketscreener.com/quote/stock/TEVA-PHARMACEUTICAL-INDUS-40246797/news/New-Pharmacokinetic-Modeling-Data-Presented-by-Teva-Simulates-Clinical-Profiles-of-Schizophrenia-Pat-46381951/?utm_medium=RSS&utm_content=20240406.